Biogen, AbbVie drug slows MS episodes, safety issues recur

June 16, 2014 2:00 PM

6 0

Biogen, AbbVie drug slows MS episodes, safety issues recur

(Reuters) - A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

The mixed results were seen in a Phase III international study of the medicine, called daclizumab, that involved more than 1,800 patients with relapsing-remitting multiple sclerosis - the most common form of MS which can lead to disability and paralysis.

Read more

To category page

Loading...